Articles tagged with Squamous Cell Carcinoma
A new study examines the KEYNOTE-689 trial cohort to determine whether anticipated survival benefits outweigh the costs based on a standard threshold. Patients with higher combined positive scores saw significant quality-adjusted life years gains with perioperative pembrolizumab.
Researchers discovered that immunosuppressed patients with non-melanoma skin cancer have macrophages that fail to communicate effectively, leading to tumor progression. The study's findings suggest that boosting the functionality of these immune cells may lead to new treatment opportunities for these patients.
Researchers from The University of Osaka identified a unique genetic pattern in carcinoma cuniculatum, a rare type of oral cancer with slower growth and lower risk of spread. This discovery may lead to improved diagnosis and targeted treatment for this challenging-to-diagnose condition.
A nationwide study found that adolescents and young adults with prior cervical high-grade squamous intraepithelial lesion (HSIL) are at a higher risk of cardiovascular events and mortality. The study suggests that women with prior HSIL should be more closely monitored for cardiovascular disease and prevention strategies should be imple...
A recent study analyzing over 1,400 cases of squamous cell carcinoma found that more aggressive histopathological variants occur at a rate of 4.6%, significantly lower than previous estimates. The researchers highlight the importance of considering regional differences in tumor origin and behavior to improve treatment outcomes.
Researchers found that patients with low physical activity levels are at higher risk of developing lymphedema. The study used a lymph scanner to measure tissue water and identified limits for what is considered lymphedema. Regular physical activity may help reduce the risk of lymphedema after head and neck cancer treatment.
Researchers at the University of Arizona Comprehensive Cancer Center are investigating novel immune-based approaches to prevent keratinocytic skin cancers. They aim to identify early immune signals that can activate the body's own immune defenses to prevent cancer before it starts.
Researchers developed a genomic model to tailor radiation doses to individual patients with HPV-positive throat cancer. The study found that higher scores on the Genomic Adjusted Radiation Dose (GARD) model were associated with improved survival outcomes, even when patients received the same radiation dose.
A simple AI model has been shown to accurately assess the aggressiveness of squamous cell carcinoma, a common form of skin cancer. The study found that two clinical features - ulcerated and flat skin surfaces - were strongly associated with more aggressive tumor growth.
A new class of targeted therapy showed promise in treating head and neck squamous cell carcinoma (HNSCC) in pet cats, with 35% of patients experiencing controlled disease. The drug, which targets the transcription factor STAT3, also raised levels of PD-1, a protein associated with an immune response to cancer.
Researchers found that cigarette smoke and reduced DNA repair capacity combine to increase cancer risk, with normal lung cells showing extensive damage after smoke exposure. The study's findings support a 'double hit' model, highlighting the critical role of XPC protein in preventing DNA damage.
A phase 2 trial found that combining avelumab and cetuximab significantly extended median progression-free survival in patients with advanced cutaneous squamous cell carcinoma. The combination showed synergistic effects, suggesting a potential new standard of care for this patient population.
Researchers identified C5aR1 as a novel prognostic biomarker and potential therapeutic target for treating metastatic skin cancer. Elevated C5aR1 presence suggests increased metastasis risk and poor survival in patients with cutaneous squamous cell carcinoma.
The study evaluated the mutation profiles of lung squamous cell carcinoma (LSCC) detected by next-generation sequencing to assess relationships with clinicopathological parameters. Detection of mutations revealed associations between certain genes, such as PIK3CA and NF1, with specific histopathological features.
A Phase 2 clinical trial found that a neoadjuvant chemo-immunotherapy regimen achieved a 53% deep response rate, exceeding historical data with chemotherapy alone. The treatment approach led to impressive survival outcomes and fewer toxic side effects in patients with advanced HPV-negative head and neck cancer.
The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for anal cancer, providing guidance on treatment options and techniques. The guideline recommends a combination of radiation therapy and drug therapy as the standard of care, with intensity-modulated radiation therapy (IM...
Researchers analyzed pre-treatment CT scans of patients with head and neck squamous cell carcinoma to identify radiomic biomarkers that can predict the aggressiveness of the disease and its response to treatment. These biomarkers may lead to more targeted therapies and improved survival outcomes for patients.
Researchers developed a novel microscopy technique to study metabolic changes in individual cancer cells at the single-cell level. They found that radiation treatment caused significant metabolic shifts in head and neck squamous cell carcinoma cells, particularly through the activation of HIF-1α.
A new study by Mass General Brigham researchers reveals that a novel immunotherapy can eliminate precancerous spots and prevent skin cancer through the activation of specific immune cells. The therapy successfully cleared over 95% of facial lesions and showed long-term efficacy, with benefits lasting up to five years after treatment.
Researchers developed a new imaging technique using fluorescence-guided surgery to enhance visibility of tumors and nerves during head and neck cancer surgery. The technique uses two near-infrared fluorophores, one for tumors and another for facial nerves, allowing for clear differentiation between cancerous tissues and nerves.
Researchers from National Cancer Centre Singapore have successfully used exosomes to target squamous cell cancer tumours resistant to EGFR-TKIs. The study found that exosomes carrying a specific protein can increase sensitivity to TKIs in both lab and mouse models, providing new therapeutic solutions for patients with poor prognosis.
A phase II clinical trial found that combining sEphB4-HSA with pembrolizumab improved outcomes in HPV-negative, EphrinB2-positive head and neck squamous cell carcinoma patients. The combination showed a favorable toxicity profile and activity, particularly among those with HNSCC.
Researchers investigated the use of CYFRA 21-1 and CXCR1/2 levels for detecting recurrence in stage III SCLC. The study found that a combined model can detect recurrence with high accuracy, and adjusting treatment regimens based on these values may improve patient outcomes.
New findings in The American Journal of Pathology indicate that periostin promotes esophageal squamous cell carcinoma progression by enhancing cancer and stromal cell migration in cancer-associated fibroblasts. Periostin may be a promising therapeutic target for treating ESCC.
Seven high-impact studies will be showcased, exploring novel therapies and improving treatment outcomes for patients with head and neck squamous cell carcinoma. These findings highlight advancements in immunotherapy, risk-directed adjuvant therapy, and FDG-PET-based selective de-escalation of radiotherapy.
A recent study by Pusan National University scientists discovered the crucial role of PKM gene and EPHA2 pathway in HNSCC development. The research highlights the importance of HPV infection status in shaping the tumor microenvironment, enabling precision medicine for targeted treatment.
A large retrospective cohort analysis found that neoadjuvant chemotherapy improved overall and progression-free survival for locally advanced penile squamous cell carcinoma patients. The study also showed that platinum-based chemotherapy was well-tolerated, with low treatment-related mortality.
Researchers identified senescence-related tumor microenvironment genes associated with poor prognosis, genetic alterations, and reduced responsiveness to immunotherapy in HNSC. The study highlights the importance of precision medicine approaches for personalized treatment.
Researchers found that high levels of FSP1 are associated with relapse after cisplatin treatment in head and neck squamous cell carcinoma. Targeting FSP1 can attenuate tumor stemness and downregulate invasion and metastatic rates, suggesting a potential new approach for treating drug-tolerant persister cancer cells.
A new study found that patients treated at community cancer centers have poorer survival rates compared to those at academic medical centers. The study analyzed data from over 20,000 patients with HPV-related oropharyngeal squamous cell cancers.
A new study at the University of Turku discovered that plixorafenib inhibits multiple signaling pathways in cutaneous squamous cell carcinoma, showing promise for treatment. The drug was originally developed for melanoma and lung cancer, but its effectiveness against cSCC is significant.
A new study reveals a link between the removal of the FGFR1 protein's extracellular domain and a significant decrease in tumour volume. This finding offers a potential new avenue of treatment for patients with squamous cell carcinoma of the lungs, who have shown limited success with current therapies.
Researchers at H. Lee Moffitt Cancer Center & Research Institute have identified a new drug, NFX-179, that can prevent the development of cutaneous squamous cell carcinoma with minimal side effects. The topical application of NFX-179 gel was shown to reduce tumor formation by up to 92% in pre-clinical models.
A new study found that a shorter radiation treatment course is just as effective as a longer schedule for patients with non-HPV-related locally advanced disease. Delivering fewer, but higher doses of radiation was associated with similar tumor control and late-term side effects.
Research reveals strong associations between oral health and survival among people diagnosed with head and neck cancer, with better oral health linked to increased survival. Frequent dental visits were found to be associated with earlier cancer diagnosis and less deadly disease stages.
Researchers highlight the need for effective treatment strategies for adenoid cystic carcinoma (ACC) of the head and neck, which is a highly malignant tumor with variable localizations. Proton therapy shows decisive advantages in long-term survival rates for ACC.
A new study identifies two distinct subtypes of human papillomavirus-positive head and neck cancers with different treatment outcomes. Tumors with high NF-kB activity are more responsive to radiation therapy, leading to improved patient survival.
A new study found that cetuximab plus radiotherapy is an active treatment option for locally advanced cutaneous squamous cell skin cancer, with an objective response rate of 83.2%. The treatment was well-tolerated, with most patients experiencing mild acneiform skin rash or fatigue.
Head and neck squamous cell carcinoma patients face substantial burden of uncontrolled cardiovascular risk factors, leading to increased risk of stroke and heart attack. Modifiable CV risk factor control is crucial in reducing the risk of adverse cardiovascular events and death among these patients.
Researchers found that participants with lower written health literacy experienced longer delays in initiating postoperative radiation therapy. The study controlled for demographic and clinical factors, highlighting the importance of health literacy in cancer care.
Researchers developed a non-invasive diagnostic test called PANDORA that accurately identified patients with oral squamous cell carcinoma and pre-cancerous conditions. The test, which measures dielectrophoresis in cells, shows over 92% accuracy in detecting oral cancer.
A study found that individuals with a history of atopic diseases, such as allergic asthma or rhinitis, had significantly lower rates of melanoma and skin cancer compared to non-atopic individuals. The risk of melanoma was up to 50% lower in atopic patients, and the overall risk of skin cancer was also reduced.
Researchers have identified a new marker that indicates when skin cancer cells are preparing to metastasise. The study shows that tumour cells alter their metabolism to feed on bad cholesterol molecules, allowing them to survive migration and proliferation in other organs.
Researchers identify the minimum contribution of TACC3 for FGFR3-TACC3 fusion protein activation, revealing a novel target for treating FGFR translocation-driven cancers. The study shows that clinically identified FGFR3-TACC3 fusion proteins differ in biological activity depending on specific breakpoints.
Researchers investigated the effects of everolimus on the STAT3/HIF-1α/VEGF pathway in TP53 mutant cell lines and xenograft models. Everolimus treatment significantly inhibited cell growth and reduced tumor angiogenesis and lymphangiogenesis.
Regular use of vitamin D supplements was associated with a significantly reduced risk of melanoma and better skin cancer classification compared to non-users. However, the study did not find a significant association between vitamin D use and other skin changes or severity of photoaging.
A study published in Nature reveals that cancer stem cells' miscommunication with their environment can trigger a self-perpetuating series of events leading to malignancy. Leptin signaling plays a surprising role in this process, which could be blocked to prevent tumor progression.
A recent study published in Oncotarget reveals that Nectin-4 is widely expressed in head and neck squamous cell carcinoma (HNSCC), with significant correlations to clinico-pathological parameters. Non-smokers and p16-positive HNSCC showed higher expression of Nectin-4, leading to better survival rates for positive tumors.
A phase II clinical trial has demonstrated the effectiveness of nivolumab, an immune checkpoint inhibitor, in treating advanced cutaneous squamous cell carcinoma. The study found a significant response rate of 58.3% among patients who received nivolumab, supporting its use as a standard therapy for this disease.
The NRG-HN004 trial found that radiotherapy with durvalumab did not improve progression-free survival or overall survival compared to cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma who have a contraindication to cisplatin. The study highlighted the need for further research in this population.
In an international clinical trial, 63.3% of patients with stage II-IV cutaneous squamous cell carcinoma saw their tumors nearly or completely disappear when treated with immunotherapy before surgery. The anti-PD1 therapy cemiplimab was well-tolerated and met its primary endpoint with a pathologic complete response rate of 50.6%.
Research suggests that NF-κB over-activation is associated with improved outcomes in patients with HPV-positive head and neck cancer. An RNA-based classifier trained on tumors with specific mutations may improve prognostic classification, aiding in treatment personalization.
A minimally invasive device combined with molecular biomarkers has shown a 90% success rate in detecting esophageal squamous cell carcinoma, the predominant subtype of esophageal cancer. Early detection is crucial to improve survival rates, as symptoms often become apparent too late for effective treatment.
A study has identified a new protein, Creb-binding protein (CBP), as a prognostic marker for above-average patient survival in HPV-positive head and neck carcinoma. CBP inhibitors are being developed as targeted therapies that can improve quality of life by reducing side effects associated with conventional chemotherapy or radiotherapy.
Patients with Merkel cell carcinoma face a high risk of recurrence, with 95% of cases occurring within the first three years. The study found that advanced age, male sex, immunosuppression, and known primary lesions are associated with higher recurrence rates, highlighting the need for targeted surveillance efforts.
The European Research Council has awarded Kai Kretzschmar a Starting Grant to systematically characterise oral epithelial stem cells. This will help decipher the mechanisms underlying the diversity of the oral epithelium and its contribution to oral squamous cell carcinomas.
A recent study has identified a new mechanism by which oral cancer cells acquire radioresistance through the transfer of microRNA, specifically miR-503-3p. This discovery brings hope for the development of new treatments for radiation-resistant oral cancer.
The study evaluated outcomes of minimally invasive esophagectomy compared to open esophagectomy in 6000 ESCC patients over 10 years. MIE was found to be an effective treatment option even for large tumors, expanding its indicated population.
A recent study by NTU Singapore has found a strong link between increasing air pollution and the rise of lung adenocarcinoma, a type of cancer. The study also discovered that declining smoking rates are associated with lower incidence of lung squamous cell carcinoma.
Non-melanoma basal and squamous cell skin cancers saw a 30% rise in Ontario over 15 years, mostly among people under age 35. The annual mortality rates increased by almost 5-fold, with males experiencing higher rates than females.